IBD Market Expansion Tillotts focuses on inflammatory bowel disease therapies (IBD) and has launched products like Octasa for UC across multiple regions. Potential sales opportunity lies in expanding GI specialist partnerships and distributor networks in high-prevalence markets for UC and CDi, leveraging their in-licensing strategy and existing European footprint.

Oral Antibody Pipeline Recent news indicates development of innovative oral antibody therapy for ulcerative colitis in collaboration with Mage Biologics. This presents a cross-sell or co-development avenue with gastroenterology clinics and specialty pharmacies targeting UC patients seeking convenient oral biologic options.

Strategic Partnerships Tillotts has formed alliances with TVM Capital Life Science to advance novel UC therapies, signaling openness to co-investments and channel collaborations. Business development can pursue similar VC-backed partnerships and regional licensing deals to accelerate market access in underserved territories.

Product Portfolio Growth Introduction of higher-dose formulations like Octasa 800 mg and 1600 mg indicates a strategy to address varying disease activity levels. Opportunities exist to cross-sell higher-dose or alternate-release products to physicians treating moderately to severely active UC and to expand into new markets with updated pediatric or adult dosing guidelines.

Geographic Footprint With operations in Switzerland and abroad and in-licensed products marketed in around 65 countries through affiliates and partners, Tillotts already has a global distribution network. Sales strategies can target gastroenterology clinics, hospital channels, and regional distributors in high-need markets, emphasizing access programs and payer engagement to support adoption.